Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.
Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.
复制标题
MicroRNA 在 EGFR 靶向肺癌治疗中的新作用
DOI：
10.1155/2015/672759
复制
发表时间：
2015
影响因子：
--
通讯作者：
Liu X
中科院分区：
文献类型：
--
作者：
Han F;He J;Li F;Yang J;Wei J;Cho WC;Liu X
肺癌是世界范围内癌症死亡的主要原因。其发病机制已部分阐明，其中表皮生长因子受体(EGFR)通路是已知的在肿瘤发生中起关键作用的信号转导通路之一。EGFR信号转导失调常见于肺癌。有效抑制EGFR信号通路的策略已经成为开发抗癌治疗药物的基础。然而，大多数抗EGFR靶向药物由于产生耐药性而未能抑制癌症的进展。因此，对抗EGFR药物耐药机制的研究可能为使用抗EGFR药物治疗肺癌提供重要发现。最近，越来越多的miRNAs与肺癌细胞对抗EGFR药物的耐药性相关，表明miRNAs可能成为抗EGFR治疗的新靶点和/或有希望的预测生物标记物。在本文中，我们综述了miRNAs在调节EGFR信号和肺癌细胞对抗EGFR治疗的耐药性方面的新作用。我们还强调了支持将miRNAs用作对抗EGFR药物的反应的生物标志物和作为规避肺癌细胞对EGFR抑制剂的耐药性的新的治疗靶点的证据。
Lung cancer is a leading cause of cancer mortality worldwide. Several molecular pathways underlying mechanisms of this disease have been partly elucidated, among which the epidermal growth factor receptor (EGFR) pathway is one of the well-known signaling cascades that plays a critical role in tumorigenesis. Dysregulation of the EGFR signaling is frequently found in lung cancer. The strategies to effectively inhibit EGFR signaling pathway have been mounted for developing anticancer therapeutic agents. However, most anti-EGFR-targeted agents fail to repress cancer progression because of developing drug-resistance. Therefore, studies of the mechanisms underpinning the resistance toward anti-EGFR agents may provide important findings for lung cancer treatment using anti-EGFR therapies. Recently, increasing numbers of miRNAs are correlated with the drug resistance of lung cancer cells to anti-EGFR agents, indicating that miRNAs may serve as novel targets and/or promising predictive biomarkers for anti-EGFR therapy. In this paper, we summarize the emerging role of miRNAs as regulators to modulate the EGFR signaling and the resistance of lung cancer cells to anti-EGFR therapy. We also highlight the evidence supporting the use of miRNAs as biomarkers for response to anti-EGFR agents and as novel therapeutic targets to circumvent the resistance of lung cancer cells to EGFR inhibitors.